A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered As a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Trastuzumab; Vinorelbine
Indications Breast cancer; HER2 positive breast cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Chugai Pharmaceutical; Roche

Most Recent Events

26 Dec 2024 Planned End Date changed from 31 Dec 2025 to 31 May 2026.
26 Dec 2024 Planned primary completion date changed from 31 Dec 2025 to 31 May 2026.
19 Apr 2023 Planned End Date changed from 31 May 2024 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight